ES2225570T3 - Rgd (arg-gly-asp) acoplado a neuropeptidos. - Google Patents
Rgd (arg-gly-asp) acoplado a neuropeptidos.Info
- Publication number
- ES2225570T3 ES2225570T3 ES01947245T ES01947245T ES2225570T3 ES 2225570 T3 ES2225570 T3 ES 2225570T3 ES 01947245 T ES01947245 T ES 01947245T ES 01947245 T ES01947245 T ES 01947245T ES 2225570 T3 ES2225570 T3 ES 2225570T3
- Authority
- ES
- Spain
- Prior art keywords
- peptide
- gly
- asp
- receptor
- coupled
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 title abstract 3
- 108090000189 Neuropeptides Proteins 0.000 title abstract 2
- 108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 2
- 108010051479 Bombesin Proteins 0.000 abstract 1
- 102000013585 Bombesin Human genes 0.000 abstract 1
- 102400000921 Gastrin Human genes 0.000 abstract 1
- 108010052343 Gastrins Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102000028517 Neuropeptide receptor Human genes 0.000 abstract 1
- 108070000018 Neuropeptide receptor Proteins 0.000 abstract 1
- 102000003797 Neuropeptides Human genes 0.000 abstract 1
- 108010004684 Pituitary adenylate cyclase-activating polypeptide Proteins 0.000 abstract 1
- 102000002808 Pituitary adenylate cyclase-activating polypeptide Human genes 0.000 abstract 1
- 108050001286 Somatostatin Receptor Proteins 0.000 abstract 1
- 102000011096 Somatostatin receptor Human genes 0.000 abstract 1
- 102000055135 Vasoactive Intestinal Peptide Human genes 0.000 abstract 1
- 108010003205 Vasoactive Intestinal Peptide Proteins 0.000 abstract 1
- 230000003213 activating effect Effects 0.000 abstract 1
- 108060000200 adenylate cyclase Proteins 0.000 abstract 1
- 102000030621 adenylate cyclase Human genes 0.000 abstract 1
- 150000001413 amino acids Chemical group 0.000 abstract 1
- DNDCVAGJPBKION-DOPDSADYSA-N bombesin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1NC2=CC=CC=C2C=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1NC(=O)CC1)C(C)C)C1=CN=CN1 DNDCVAGJPBKION-DOPDSADYSA-N 0.000 abstract 1
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 abstract 1
- CWWARWOPSKGELM-SARDKLJWSA-N methyl (2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-5-amino-2-[[(2s)-5-amino-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s)-1-[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-5 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)OC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 CWWARWOPSKGELM-SARDKLJWSA-N 0.000 abstract 1
- 230000001817 pituitary effect Effects 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 229940035636 somatostatin and analogues Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1019—Tetrapeptides with the first amino acid being basic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/082—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being a RGD-containing peptide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/083—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being octreotide or a somatostatin-receptor-binding peptide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/595—Gastrins; Cholecystokinins [CCK]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/655—Somatostatins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/655—Somatostatins
- C07K14/6555—Somatostatins at least 1 amino acid in D-form
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/75—Fibrinogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0815—Tripeptides with the first amino acid being basic
- C07K5/0817—Tripeptides with the first amino acid being basic the first amino acid being Arg
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
- C07K7/086—Bombesin; Related peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/22—Tachykinins, e.g. Eledoisins, Substance P; Related peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Endocrinology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Compuestos que tienen una afinidad de unión tanto por el receptor ávâ3 como por el receptor de neuropéptido, en particular el receptor de la somatostatina y, en consecuencia, tienen una afinidad global frente a los tumores mejorada; tales compuestos comprenden una primera parte del péptido que contiene al menos una vez la secuencia de aminoácidos Arg-Gly-Asp y una segunda parte del péptido acoplada a la anterior, opcionalmente vía un enlazador; tal segunda parte del péptido es un neuropéptido seleccionado del grupo constituido por CCK, gastrina, sustancia P, bombesina, VIP (péptido intestinal vasoactivo), PACAP (péptido activador de la adenilato ciclasa de la pituitaria), somatostatina y análogos de éstos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP00201499 | 2000-04-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2225570T3 true ES2225570T3 (es) | 2005-03-16 |
Family
ID=8171409
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES01947245T Expired - Lifetime ES2225570T3 (es) | 2000-04-26 | 2001-04-26 | Rgd (arg-gly-asp) acoplado a neuropeptidos. |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US7202330B2 (es) |
| EP (2) | EP1452543A3 (es) |
| JP (1) | JP2004517034A (es) |
| AT (1) | ATE272074T1 (es) |
| AU (2) | AU2001268982B8 (es) |
| CA (1) | CA2407514C (es) |
| CZ (1) | CZ20023539A3 (es) |
| DE (1) | DE60104552T2 (es) |
| ES (1) | ES2225570T3 (es) |
| HU (1) | HUP0301571A2 (es) |
| IL (1) | IL152466A0 (es) |
| NO (1) | NO20025064L (es) |
| NZ (1) | NZ522200A (es) |
| PL (1) | PL202279B1 (es) |
| WO (1) | WO2001081426A2 (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ20023539A3 (cs) | 2000-04-26 | 2003-09-17 | Biosynthema, Inc. | Sloučeniny s vaznou afinitou pro alfa v beta3 - receptory a pro (neuro)peptidové receptory |
| US7122622B2 (en) | 2002-04-16 | 2006-10-17 | Biosynthema Inc. | Peptide compounds having improved binding affinity to somatostatin receptors |
| EP1358890A1 (en) * | 2002-05-03 | 2003-11-05 | BioSynthema, Inc | Benzothienyl analogue of somatostatine, selective for certain somatostatin receptors |
| EP1614695A4 (en) * | 2003-03-31 | 2006-10-04 | Hayashibara Biochem Lab | POLYPEPTIDE |
| US20070025910A1 (en) * | 2005-07-29 | 2007-02-01 | Norenberg Jeffrey P | Anticancer therapy |
| MX2009000905A (es) | 2006-07-24 | 2009-02-04 | Procter & Gamble | Proceso para epimerizar ciclohexenil cetonas y su aplicacion en proceso de condensacion aldol. |
| KR100987592B1 (ko) * | 2008-03-10 | 2010-10-12 | 경북대학교 산학협력단 | 암진단용 ｍｒ 조영제와 그 제조방법 |
| US9517201B2 (en) * | 2008-04-04 | 2016-12-13 | Rutgers, The State University Of New Jersey | Nanocarrier and nanogel compositions |
| US8263133B2 (en) * | 2009-02-18 | 2012-09-11 | The Regents Of The University Of California | Multivalent clustering targeting strategy for drug carriers |
| CN102260352B (zh) * | 2010-05-28 | 2013-11-20 | 山东先声麦得津生物制药有限公司 | 靶向性白细胞介素融合蛋白及其制备方法与应用 |
| US9775803B2 (en) | 2011-10-19 | 2017-10-03 | Samsung Electronics Co., Ltd. | Liposome comprising elastin-like polypeptide and tumor cell targeting material and use thereof |
| WO2014081655A1 (en) * | 2012-11-21 | 2014-05-30 | Serene Oncology, Llc | Tin-1 17m comprising somatostatin receptor binding compounds |
| DK3568205T3 (da) | 2017-01-12 | 2023-10-09 | Radiomedix Inc | Behandling af cancerceller, der overeksprimerer somatostatinreceptorer ved at anvende radioisotop-chelaterede ocreotid-derivater |
| CN106967149A (zh) * | 2017-05-04 | 2017-07-21 | 苏州强耀生物科技有限公司 | 一种棕榈酰化修饰的半胱氨酸多肽的制备方法 |
| PL238941B1 (pl) * | 2018-04-04 | 2021-10-25 | Gdanski Univ Medyczny | Związki chemiczne o działaniu przeciwuszkodzeniowym i/lub neuroprotekcyjnym |
| CN116510033B (zh) * | 2023-03-09 | 2024-03-19 | 哈尔滨吉象隆生物技术有限公司 | 一种抗肿瘤的ppc药物及其制备方法与应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2878341B2 (ja) * | 1989-03-03 | 1999-04-05 | 学校法人藤田学園 | 人工機能性ポリペプチド |
| US5843903A (en) * | 1995-11-27 | 1998-12-01 | The Administrators Of The Tulane Educational Fund | Targeted cytotoxic anthracycline analogs |
| CZ20023539A3 (cs) | 2000-04-26 | 2003-09-17 | Biosynthema, Inc. | Sloučeniny s vaznou afinitou pro alfa v beta3 - receptory a pro (neuro)peptidové receptory |
-
2001
- 2001-04-26 CZ CZ20023539A patent/CZ20023539A3/cs unknown
- 2001-04-26 DE DE60104552T patent/DE60104552T2/de not_active Expired - Lifetime
- 2001-04-26 AT AT01947245T patent/ATE272074T1/de not_active IP Right Cessation
- 2001-04-26 AU AU2001268982A patent/AU2001268982B8/en not_active Ceased
- 2001-04-26 IL IL15246601A patent/IL152466A0/xx unknown
- 2001-04-26 ES ES01947245T patent/ES2225570T3/es not_active Expired - Lifetime
- 2001-04-26 AU AU6898201A patent/AU6898201A/xx active Pending
- 2001-04-26 PL PL357246A patent/PL202279B1/pl not_active IP Right Cessation
- 2001-04-26 CA CA2407514A patent/CA2407514C/en not_active Expired - Lifetime
- 2001-04-26 WO PCT/EP2001/004764 patent/WO2001081426A2/en active IP Right Grant
- 2001-04-26 NZ NZ522200A patent/NZ522200A/en unknown
- 2001-04-26 US US10/258,766 patent/US7202330B2/en not_active Expired - Lifetime
- 2001-04-26 HU HU0301571A patent/HUP0301571A2/hu unknown
- 2001-04-26 EP EP04101401A patent/EP1452543A3/en not_active Withdrawn
- 2001-04-26 EP EP01947245A patent/EP1301540B1/en not_active Expired - Lifetime
- 2001-04-26 JP JP2001578513A patent/JP2004517034A/ja active Pending
-
2002
- 2002-10-22 NO NO20025064A patent/NO20025064L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| NO20025064L (no) | 2002-12-20 |
| CA2407514C (en) | 2011-03-29 |
| WO2001081426A3 (en) | 2002-06-27 |
| NZ522200A (en) | 2004-07-30 |
| AU2001268982B8 (en) | 2006-08-03 |
| NO20025064D0 (no) | 2002-10-22 |
| AU6898201A (en) | 2001-11-07 |
| HUP0301571A2 (hu) | 2003-09-29 |
| EP1301540A2 (en) | 2003-04-16 |
| EP1301540B1 (en) | 2004-07-28 |
| IL152466A0 (en) | 2003-05-29 |
| DE60104552T2 (de) | 2005-09-01 |
| US20040136907A1 (en) | 2004-07-15 |
| DE60104552D1 (de) | 2004-09-02 |
| PL202279B1 (pl) | 2009-06-30 |
| PL357246A1 (en) | 2004-07-26 |
| US7202330B2 (en) | 2007-04-10 |
| AU2001268982B2 (en) | 2006-06-15 |
| WO2001081426A2 (en) | 2001-11-01 |
| CA2407514A1 (en) | 2001-11-01 |
| EP1452543A2 (en) | 2004-09-01 |
| ATE272074T1 (de) | 2004-08-15 |
| JP2004517034A (ja) | 2004-06-10 |
| EP1452543A3 (en) | 2005-08-03 |
| CZ20023539A3 (cs) | 2003-09-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2225570T3 (es) | Rgd (arg-gly-asp) acoplado a neuropeptidos. | |
| Langer et al. | Peptides as carrier for tumor diagnosis and treatment | |
| US8691761B2 (en) | Somatostatin receptor 2 antagonists | |
| Heppeler et al. | Receptor targeting for tumor localisation and therapy with radiopeptides | |
| CN100418585C (zh) | 稳定的放射性药物组合物及制备方法 | |
| Okarvi | Peptide-based radiopharmaceuticals and cytotoxic conjugates: potential tools against cancer | |
| TWI515011B (zh) | 鈴蟾素類似物胜肽拮抗劑共軛物 | |
| EP0835263B1 (en) | Somatostatin peptides | |
| SK281963B6 (sk) | Zlúčeniny ovplyvňujúce uvoľňovanie rastového hormónu, farmaceutické prostriedky s ich obsahom a ich použitie | |
| JP2008511557A5 (es) | ||
| Reubi | Targeting CCK receptors in human cancers | |
| ES2266616T3 (es) | Analogos de somatostatina que se unen a todos los receptores de somatostatina y su uso. | |
| JPH08503924A (ja) | 造影および治療用途の放射性標識ソマトスタチン誘導ペプチド | |
| Beck-Sickinger et al. | Targeted tumor diagnosis and therapy with peptide hormones as radiopharmaceuticals | |
| Rezazadeh et al. | Tumor targeting with 99mTc radiolabeled peptides: Clinical application and recent development | |
| NO20010284D0 (no) | Peptidanaloger av hypofyse adenylat cyclase-aktiverende polypeptid (PACAP) | |
| Zwanziger et al. | Radiometal targeted tumor diagnosis and therapy with peptide hormones | |
| de Castiglione et al. | Bombesin receptor antagonists | |
| BR0305039A (pt) | Uso de compostos que possuem a atividade biológica de peptìdeo vasoativo intestinal para o tratamento da sarcoidose | |
| Ruzza et al. | Peptide-receptor ligands and multivalent approach | |
| Liang et al. | Specific binding of an immunoreactive and biologically active 125I-labeled N (1) acylated substance P derivative to parotid cells | |
| Campbell et al. | Hormonal control of avian pancreas by gastrin-releasing peptide from the proventriculus | |
| Hoffmann et al. | Structure-affinity studies of C-terminally modified analogs of neuropeptide Y led to a novel class of peptidic Y1 receptor antagonist | |
| Graham et al. | A general method for functionalising both the C-and N-terminals of Tyr3-octreotate | |
| Chinol et al. | Radionuclide peptide cancer therapy |